| Recruitment status | Completed |
| Unique ID issued by UMIN | C000000155 |
| Receipt No. | R000000223 |
| Official scientific title of the study | randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA |
| Date of disclosure of the study information | 2005/10/01 |
| Last modified on | 2017/06/12 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA | |
| Title of the study (Brief title) | randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA | |
| Region |
|
|
| Condition | ||
| Condition | ovarian cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The combination of paclitaxel and carboplatin every 3 weeks is considered as a standard first line chemotherapy for the of patients with advanced ovarian cancer. However,this treatment often produced severe neurotoxicity. A randomized trial demonstrated that the combination of docetaxel and carboplatin had a similiar efficacy to paclitaxel and carboplatin. The treatment had less neurotoxicity,but greater myelosuppression compared with paclitaxel-carboplatin. On the other hand, and weekly paclitaxel as substitute for 3 weeks and carboplatin was reported to have similiar response and less neurotoxicity. Our aim is to examine efficacy ety of docetaxel-carboplatin versus weekly paclitaxel and carboplatin for advanced ovarian cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | progression free survival |
| Key secondary outcomes | quality of life ,safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Single blind -participants are blinded |
| Control | Uncontrolled |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is considered as a block. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | docetaxel and carboplatin | |
| Interventions/Control_2 | weekly paclitaxel and carboplatin | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Patients with histologically or cytologically confirmed epitheral ovarian cancer, fallopian tubal cancer or peritoneal cancer. performance status(ECOG)0-2. no prior chemotherapy. adequate levels of bone marrow,hepatic,and renal function. n. no heart failure and pulmonary disease. no active infection. no
other malignancies. signing of an informed consent document. |
|||
| Key exclusion criteria | pregnant or nursing woman
|
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Yamaguchi |
| Organization | osaka medical college |
| Division name | department of obstetrics and gynecology |
| Address | Daigakucho2-7 Takatuki city Osaka Japan |
| TEL | 0726-83-1221 |
| Public contact | |
| Name of contact person | Kenichi Hosokawa |
| Organization | Kyoto Prefectual University |
| Division name | department of obstetrics and gynecology |
| Address | Kajiicho465 Kamigyoku Kyoto city Japan |
| TEL | 075-251-5560 |
| Homepage URL | |
| hosokawa@koto.kpu-m.ac.jp | |
| Sponsor | |
| Institute | Osaka Medical College |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kansai Clinical Oncology Group |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000223 |